New England Consortium

Principal Investigators:
Gail D’Onofrio, MD, MS [email]
Yale University School of Medicine
Chair, Department of Emergency Medicine
464 Congress Avenue
Suite 260
New Haven, CT 06519

Roger D. Weiss, MD [email]
Department of Psychiatry
Harvard Medical School
Division of Alcohol and Drug Abuse
McLean Hospital
115 Mill St.
Belmont, MA 02478-9106

Related Resources

Node web site
NIDA web site

The New England Consortium was established in 2010, combining into a single node both the Regional Research and Training Centers and the Community Treatment Programs of the original New England and Northern New England nodes.

It includes programs in Massachusetts, Connecticut, Maine, and Rhode Island.

Grantee Institutions: McLean Hospital, Harvard University, Yale University

Protocol Involvement

• CTN-0003: Suboxone (Buprenorphine / Naloxone) Taper: A Comparison of Taper Schedules
• CTN-0004: MET (Motivational Enhancement Treatment) to Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse
• CTN-0005: MI (Motivational Interviewing) to Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse
• CTN-0006: Motivational Incentives for Enhanced Drug Abuse Recovery: Drug Free Clinics
• CTN-0010: Buprenorphine/Naloxone-Facilitated Rehabilitation for Opioid Dependent Adolescents/Young Adults
• CTN-0016: Patient Feedback: A Performance Improvement Study in Outpatient Addiction Treatment
• CTN-0017: HIV and HCV Intervention in Drug Treatment Settings
• CTN-0018: Reducing HIV/STD Risk Behaviors: A Research Study for Men in Drug Abuse Treatment
• CTN-0019: Reducing HIV/STD Risk Behaviors: A Research Study for Women in Drug Abuse Treatment
• CTN-0020: Job Seekers Training for Patients with Drug Dependence
• CTN-0021: Motivational Enhancement Treatment to Improve Treatment Engagement and Outcome for Spanish-Speaking Individuals Seeking Treatment for Substance Abuse
• CTN-0027: Starting Treatment with Agonist Replacement Therapies (START)
• CTN-0028: Osmotic-Release Methylphenidate for ADHD in Adolescents with Substance Use Disorders
• CTN-0029: A Pilot Study of Osmotic-Release Methylphenidate in Initiating and Maintaining Abstinence in Smokers with ADHD
• CTN-0030-A-1: Collection of Economic Data for the Prescription Opioid Addiction Treatment Study
• CTN-0030-A-2: Effects of Chronic Opioids on the Brain
• CTN-0030-A-3: Protocol Amendment to Examine Long-Term Outcomes
• CTN-0030: Prescription Opiate Abuse Treatment Study (POATS)
• CTN-0032: HIV Rapid Testing and Counseling
• CTN-0044: Web-Delivery of Evidence-Based, Psychosocial Treatment for Substance Use Disorders
• CTN-0047-A-1: Site Influences on Treatment Effects – Screening, Motivational Assessment, Referral, and Treatment in Emergency Departments (SMART-ED)
• CTN-0047: Screening Motivational Assessment and Referral to Treatment in Emergency Departments (SMART-ED): Evaluation of Screening, Brief Intervention, Referral to Treatment (SBIRT) and Booster Session for Drug Use Patients Presenting for Treatment in the Emergency Department
• CTN-0050: Long-Term Follow-Up of START Patients
• CTN-0051-A-1: Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT) Genetics Study
• CTN-0051-A-2: Treatment-As-Usual Opioid Use Outcomes Following Discharge from Detoxification and Short-Term Residential Programs Affiliated with CTN-0051
• CTN-0051: Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT)
• CTN-0053: Achieving Cannabis Cessation — Evaluating N-Acetylcysteine Treatment (ACCENT)
• CTN-0060-A-1: Validating 3 Substance Use Screening Tools for Adolescents
• CTN-0064: Linkage to Hepatitis C Virus (HCV) Care among HIV/HCV Co-infected Substance Users
• CTN-0069-A-2: The Impact of COVID-19 on Individuals with Opioid Use Disorder Who Received Emergency Department Care: A Survey Study of Project ED Health Participants and Medical Leadership at Four EDs
• CTN-0069: Opioid Use Disorder in the Emergency Department (Project ED Health)
• CTN-0080: Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs): A Pragmatic Randomized Trial Comparing Two Buprenorphine Formulations (NIH HEAL Initiative)
• CTN-0081: Emergency Medicine Opioid Data Infrastructure: Key Venue to Address Opioid Morbidity and Mortality
• CTN-0099: Emergency Department-INitiated bupreNOrphine and VAlidaTIOn Network Trial (ED-INNOVATION)
• CTN-0100: Optimizing Retention, Duration, and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy
• CTN-0125: Integrative Data Analysis of CTN Studies to Examine the Impact of Psychosocial Treatments for Black People who use Cocaine
• CTN-0126: Longitudinal Follow-up of Individuals with Opioid Use Disorder
• CTN-0131: Office-Based Methadone versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment – A Randomized Pragmatic Hybrid Effectiveness/Implementation Trial